

June 4, 2019

CURRICULUM VITAE

MARVIN A. KONSTAM, MD, FACC, FAHA, FHFSA

WIFE: Varda Konstam, PhD

CHILDREN: Amanda Danielle Konstam, Born 5/2/80
Jeremy Michael Konstam, Born 2/9/84

EDUCATION:

1971 B.A. Columbia College, Columbia University, New York, NY
1975 M.D. College of Physicians and Surgeons, Columbia University,
New York, NY

ACADEMIC APPOINTMENTS:

1975-76 Clinical Fellow in Internal Medicine, Harvard Medical School, Boston, MA
1976-78 Resident in Diagnostic Radiology, Harvard Medical School, Boston, MA
1978-79 Clinical Fellow in Internal Medicine, Harvard Medical School, Boston, MA
1979-80 Research Fellow in Internal Medicine (Cardiology), Harvard Medical School, Boston, MA
1980-81 Clinical Fellow in Internal Medicine (Cardiology), Harvard Medical School, Boston, MA
1981-85 Assistant Professor of Medicine (Cardiology), Tufts University, Boston, MA
1981-85 Assistant Professor of Radiology, Tufts University, Boston, MA
1985-89 Associate Professor of Medicine (Cardiology), Tufts University, Boston, MA
1985-90 Associate Professor of Radiology, Tufts University, Boston, MA
1989-present Professor of Medicine (Cardiology), Tufts University, Boston, MA
1990-present Professor of Radiology, Tufts University, Boston, MA

HOSPITAL APPOINTMENTS:

1975-76 Intern in Internal Medicine, Massachusetts General Hospital, Boston, MA
1976-78 Resident in Diagnostic Radiology, Massachusetts General Hospital, Boston, MA
1978-79 Resident in Internal Medicine, Massachusetts General Hospital, Boston, MA
1979-81 Fellow in Cardiology, Brigham and Women's Hospital (Peter Bent Brigham Hospital), Boston, MA
1981-85 Assistant Physician, New England Medical Center, Boston, MA
1981-85 Assistant Radiologist, New England Medical Center, Boston, MA
1981-87 Assistant Director, Adult Cardiac Catheterization Laboratory, New England Medical Center, Boston, MA
1981-89 Director, Nuclear Cardiology, New England Medical Center, Boston, MA
1984-99 Director, Heart Failure and Cardiac Transplant Center, New England Medical Center, Boston, MA
1985-present Physician, New England Medical Center, Boston, MA
1987-96 Director, Adult Cardiac Catheterization Laboratory, New England Medical Center, Boston, MA

1995-7 Acting Chief of Cardiology, New England Medical Center, Boston, MA
 1997-2007 Chief of Cardiology, New England Medical Center, Boston, MA
 1998-2001 Director, Cardiovascular Development, New England Medical Center and Lifespan of Massachusetts.

2003-present Trustee, Tufts-New England Medical Center
 2005-2007 Medical Director, Cardiovascular Product Line, Tufts-New England Medical Center
 2009-present Chief Physician Executive, The Cardiovascular Center, Tufts Medical Center

OTHER POSITIONS:

2002-2004 President, Heart Failure Society of America
 2008 President, Association of Professors of Cardiology
 2008 Senior Advisor in Cardiovascular Diseases, National Heart, Lung, and Blood Institute

CERTIFICATION

Massachusetts License (#40385), 1976
 American Board of Internal Medicine, 1979
 American Board of Radiology (Diagnostic Radiology), 1980
 American Board of Internal Medicine, Cardiovascular Diseases
 Subspecialty (#069033), 1981.
 American Board of Internal Medicine, Secondary Subspecialty in Advanced Heart
 Failure and Transplant Cardiology, 2010

MEMBERSHIPS

Phi Beta Kappa.
 Alpha Omega Alpha.
 American Heart Association (Fellow), Council on Basic Science; Council on Clinical
 Cardiology
 American College of Cardiology (Fellow), Academic Cardiology Council (Chair).
 Association of University Cardiologists
 Heart Failure Society of America (President, 2002-4) (Fellow)

HONORS AND AWARDS

The Stevelman Prize for excellence in adult cardiology, Columbia
 University, 1975.

The Bartelstone Award for excellence in pharmacology, Columbia
 University, 1975.

Citation for excellence in teaching, Tufts University School of
 Medicine, 1986.

Citation for outstanding contribution to Internal Medicine Training Program, Boston VA
 Medical Center, 1986.

Excellence in Teaching Award, Tufts University School of Medicine, 1997-8; 1998-9; 2000-2001; 2002-2003

Named among "Boston's Best Doctors", Boston Magazine, 1997, 1999.

Listed under "Best Doctors in America", Woodward and White, 1998.

Oliver Smith Award for excellence, compassion, and service, New England Medical Center, 2000

Judge, 2001; 2002 Young Investigators Awards, American College of Cardiology

Howard Gilman Foundation Distinguished Visiting Scientist. Weill Medical college of Cornell University, December, 2001

Special Honored Lecturer at Japanese Heart Failure Society meeting, 2003.

Listed among "Top Doctors". Boston Consumers Checkbook, 2003.

"Best Doctors in America", Castle Connolly and/or US News & World Report, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019

Brian A. McGovern Excellence in Education Award, 2005.

45th Annual Carl J. Wiggers Memorial Awardee and Lecturer, Case Western Reserve University, 2008

Distinguished Faculty Award; Tufts University School of Medicine, 2010

Journal article most read by Cardiologists in 2017 (Medscape Cardiology; Theheart.org): Konstam MA, Abboud F: Ejection fraction: misunderstood and overrated: Changing the paradigm in categorizing heart failure. *Circulation* 2017;135:717-719

Arnold Katz memorial lecturer at New York University School of Medicine, 2018

Lifetime Achievement Award, Heart Failure Society of America, 2018

Keynote Speaker, AHA / ACC Massachusetts Cardiology Fellows' Program: Choosing a Career, 2018

BRIEF BIOGRAPHY

Marvin A. Konstam, MD, FACC is Professor of Medicine at Tufts University School of Medicine and Chief Physician Executive of The CardioVascular Center at Tufts Medical Center. He graduated from the College of Physicians and Surgeons, Columbia University and completed his post-graduate training at Massachusetts General Hospital and Brigham and Women's Hospital. Dr. Konstam served as Chief of Cardiology at Tufts Medical Center for 10 years. Currently, as Chief Physician Executive, CardioVascular Center, Dr. Konstam directs all cardiovascular disease programs at Tufts Medical

Center. He also serves as a member of Tufts Medical Center Board of Trustees, as well as the Board of Directors of Minuteman Health. Dr. Konstam is a recipient of the Distinguished Faculty Award from Tufts University School of Medicine.

Dr. Konstam's principal academic and clinical interest is heart failure, and his primary areas of investigation are ventricular remodeling, novel pharmaceutical and device treatment, and strategies for improving quality of cardiovascular care. He was lead author and committee chair for the Agency for Health Care Policy and Research (presently AHRQ) Clinical Practice Guideline on heart failure, and has served on the Heart Failure Guideline panels of the American Heart Association (AHA) / American College of Cardiology (ACC) and of the Heart Failure Society of America (HFSA). He has served as a member of the Cardiovascular and Renal Advisory Panel of the Food and Drug Administration and has consulted for the Centers for Medicare and Medicaid Services (CMS) as a member of the Medicare Coverage Advisory Committee and in their programs for improving quality of care in heart failure.

Dr. Konstam is past President of the HFSA (2002–2004), during which time he initiated the HFSA Research Fellowship Program and played the lead role in driving the American Board of Internal Medicine's establishment of Advanced Heart Failure and Transplant Cardiology as a secondary subspecialty of Cardiology. He is also past President of the Association of Professors of Cardiology and a member of the Association of University Cardiologists. In 2008, Dr. Konstam served as Senior Advisor for Cardiovascular Diseases at the National Heart, Lung, and Blood Institute (NHLBI), providing direction to the NHLBI's extramural cardiovascular research programs. He recently served as a member of the CMS/The Joint Commission/ACC/AHA Heart Failure Technical Expert Panel and as Chair of the HFSA Nominating Committee. He currently serves as Chair of the ACC Council on Academic Cardiology, as a member of the MACRA Clinical Advisory Committee for the Centers for Medicare and Medicaid Services, and as a member of American Heart Association, Massachusetts Affiliate, Executive Leadership Team. Dr. Konstam has been named among the "Best Doctors in America" (Castle Connolly) for 14 consecutive years.

EXTRAMURAL FUNDING RECEIVED

1. American Lung Association: Right ventricular end-systolic pressure-volume relationship in pulmonary hypertension (Principal Investigator).
2. American Heart Association #840882: Anthracycline toxicity: Ventricular pressure volume analysis (Principal Investigator).
3. American Heart Association, Massachusetts Affiliate: Ventricular performance in anthracycline cardiotoxicity (Sponsor to Dr. David Weiland).
4. National Heart, Lung, and Blood Institute Individual training grant #5F32HL07133: In vivo imaging of thrombus with monoclonal antibodies specific for activated platelets (Co-Sponsor to Dr. Theresa Palabrica).
5. National Heart Lung and Blood Institute N01-HC55010: Studies of left ventricular dysfunction (participating center; Co-Investigator). Director, Radionuclide Ventricular Function Core Laboratory .
6. American Heart Association, Massachusetts Affiliate #13-524-856: Leukocyte deposition in cardiac transplant rejection. (Principal Investigator).

7. American Heart Assoc., Massachusetts Affiliate #13-418-856: Right ventricular preservation during cardiopulmonary bypass (Sponsor to Dr. Eric Eichhorn).
8. National Heart Lung and Blood Institute: Radionuclide-derived biventricular function: natural history and effect of chronic angiotensin converting enzyme inhibition. (Substudy of #5, above). (Principal Investigator)
9. National Heart Lung and Blood Institute: Individual training grant #1F32HL08338-01. Platelet activation in ischemic heart disease (Sponsor to John Golden, M.D.)
10. Losartan Medical School Grant (Merck): Effects of angiotensin II receptor blockade and angiotensin converting enzyme inhibition, alone and in combination, on cardiac growth factor expression, fibroblast proliferation, and ventricular remodeling in a rat model of myocardial infarction (Sponsor to Kenneth Taylor, M.D.)
11. Additional industry support: Sterling Winthrop Research Institute; Merrell Dow Research Institute; Warner-Lambert/Parke-Davis; Fissons Corp; Pfizer Inc; Boots Pharmaceuticals; Boeringer-Ingelheim Pharmaceuticals; Biogen Inc; Merck.
12. National Heart Lung and Blood Institute: A-II & Post-MI ventricular remodeling: Transgenic models. (Sponsor to Richard Patten, M.D.: KO-8)
13. Fannie Rippel Foundation: A system for Specialized Primary and Networked Care in Heart Failure (SPAN-CHF): A demonstration project for a program in disease management in heart failure. (Partial funding, together with below.)
14. Hewlett Packard Corporation: A system for Specialized Primary and Networked Care in Heart Failure (SPAN-CHF): A demonstration project for a program in disease management in heart failure. (Partial funding, together with above.)
15. Cardiac Performance Center (Founder and Co-Director): Core radionuclide ventricular function laboratory for major multi-center clinical trials: SOLVD (NIH); ELITE (Merck); BEST (NIH/VA; active); IMPRESS (Bristol-Myers; active); PRAISE 2 (Pfizer; active).
16. Network for Cardiovascular Clinical Studies (NeCCS) (Founder and Co-Director): A contract research organization (CRO) / site management organization (SMO) directing a nationwide network of community cardiology sites in conducting large-scale clinical trials. Contracts include: PRAISE 2 (Pfizer); MERIT (Astra); WIZARD (Pfizer) IMPRESS (Bristol-Myers); VITAL (Otsuka); Conivaptan (Parke-Davis).
17. National Heart Lung and Blood Institute: Effects of selective estrogen receptor modulation on left ventricular remodeling, endothelial function and electrophysiologic parameters. Project of a Specialized Center of Research (SCOR): SCOR P.I.: Michael Mendelsohn, M.D. Project PI: James Udelson, M.D. Role: Co-PI.
18. National Heart Lung and Blood Institute (1U10HL110342-01): Heart Failure Clinical Trial Network. New England, New York and Quebec Regional Clinical Center, 20122018. Role: PI

19. Verizon Foundation: A Multicenter Randomized Controlled Evaluation of Heart Failure Disease Management Using Advanced Telecommunications Within a Diverse Provider Network: The Specialized Primary and Networked Care in HF (SPAN-CHF) III Trial. 2013-2016. Role: PI
20. Otsuka Pharmaceuticals: Randomized, Double-Blind, Placebo controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure with Challenging Volume Management (SECRET of CHF trial). 2012-2016. Role PI.

RESEARCH TRAINEESPrimary project(s)

David Weiland, M.D. 1984-5	Ventricular performance in anthracycline cardiotoxicity
Theresa Palabrica, M.D. 1985-7	In vivo imaging of thrombus with monoclonal antibodies specific for activated platelets.
Eric Eichhorn, M.D. 1985-6 1986-7	Inotropic therapy for congestive heart failure. Right ventricular preservation during cardio-pulmonary bypass.
David Brill, M.D. 1987-8	Relationship among right ventricular systolic function, clinical status, and survival in CHF.
James Udelson, M.D. 1988-9	Diastolic performance in CHF.
John Smith, M.D. 1989-90	Platelet activation during coronary angioplasty and vascular injury.
Carey Kimmelstiel, M.D. 1989-90	Atrio-peptidase inhibition in CHF.
John Golden, M.D. 1990-91	Platelet activation in ischemic heart disease.
Kabir Chuttani, M.D. 1991-92	Mechanisms of restenosis post-angioplasty.
Richard Patten, M.D. 1993-95	Angiotensin converting enzyme effects on adrenergic activity and sensitivity.
Kenneth Taylor, M.D. 1993-95	Angiotensin receptor blockade and cardiac remodeling.
Richard Patten, M.D. 1997-2002	A-II & Post-MI ventricular remodeling: Transgenic models. (KO-8 Award)
Jenica Upshaw, M.D. 2013-2016	A Multicenter Randomized Controlled Evaluation of Heart Failure Disease Management Using Advanced Telecommunications Within a Diverse Provider Network: The Specialized Primary and Networked Care in HF (SPAN-CHF) III Trial

EDITORIAL CONSULTANT

American Federation for Clinical Research
American Journal of Cardiology
America Journal of Medicine
Annals of Internal Medicine
Archives of Internal Medicine
Cardiology (Editorial Board)
Circulation (Editorial Board)
Circulation Research
Circulation Journal (Japan) (International Advisory Board)
Clinical Research in Cardiology (Editorial Board)
European Heart Journal
Heart Failure (Editorial Board)
Hypertension
International Circulation: International Advisory Board
International Journal of Cardiology
Journal of the American College of Cardiology
JAMA
Journal of Cardiac Failure (Editorial Board)
Journal of Clinical Investigation
Journal of Disease Management (Editorial Board)
Journal of Nuclear Medicine
Lancet
New England Journal of Medicine

COMMITTEE SERVICE

Panel for Development of Clinical Practice Guideline for Diagnosis and Treatment of Heart Failure
(Agency for Health Care Policy and Research), Chairman, 1991-5

Pfizer Visiting Professorship Program in Cardiovascular Medicine Academic Advisory Committee 1992-4

Boston Consortium for Heart Transplantation Central Selection Committee 1985- (Co-Chairman, 1987-8).

Peer Review Committee, American Heart Association, Massachusetts Affiliate, 1988-1991

Radiation Safety Committee of New England Medical Center, 1991-5

Committee on Industry Support and Discretionary Funds, New England Medical Center, 1991

Committee on Conflicts of Interest, New England Medical Center, 1991-2

Committee on Department of Family Medicine, Tufts University School of Medicine, 1993

Advisory panel on heart failure, MEDCO, 1994-1995

Cardiovascular Clinical Advisory Board, MEDCO, 1995-1998

Industry Sponsored Clinical Trials Advisory Committee, New England Medical Center, 1995

West Hudson Effort Steering Committee, New England Medical Center, 1995

National panel for review of Medicare Quality Indicator System (MQIS), Congestive Heart Failure
Module, 1995

Heart Failure Society of America, Executive Council 1995-2006

Heart Failure Society of America, Secretary, 1998-2000

Heart Failure Society of America, Vice President, 2000-2

Heart Failure Society of America, President, 2002-4

U.S. Food and Drug Administration, ad hoc Advisory Committee member, 1996.

U.S. Food and Drug Administration, member, Cardiovascular and Renal Advisory Committee, 1996-2000

U.S. Food and Drug Administration, Special Government Employee 2000- Business
Development Advisory Group, New England Medical Center, 1996

Chairman, Managed Care Committee, New England Medical Center, 1996-2001

Steering Committee, PRAISE 2 (Pfizer) 1996-2000

Scientific Executive Committee, World Congress on Heart Failure, 1997- Board
Member, Cancer Center, New England Medical Center, 1997-1999

Lifespan Network Development Council 1997-2001

Steering Committee, ELITE 2 (Merck; A multinational investigation of angiotensin receptor antagonism
in heart failure) 1997-2000

Data and Safety Monitoring Board, SCD-HeFT (NIH; a nationwide investigation of implantable
cardioverter-defibrillators and amiodarone in heart failure), 1997-2004

Medical Advisory Board, MEDCO, 1998-2000

Principal Consultant, Massachusetts Hospital Association Guideline Initiative in Heart Failure, 1998-2000

The Future of Academic Cardiology: 30th Bethesda Conference writing group, 1999

American College of Cardiology / American Heart Association Writing group: Mechanical Cardiac
Support 2000: Current Applications and Future Trial Design. 2000.

American Heart Association / American College of Cardiology, Heart Failure Guideline Writing
Committee, 2000-2009

American Heart Association / American College of Cardiology joint Task Force on Quality Measures in
Heart Failure 2000-

American Heart Association Clinical Cardiology Program Committee 2001-4

Co-Chair Steering Committee, HEAAL (Merck; A multinational investigation of angiotensin receptor
antagonism in heart failure) 2001-9

COMMITTEE SERVICE (continued)

Data and Safety Monitoring Board, APPROVe Trial (Merck; rofecoxib for colonic polyps), 2002-4

Chair Steering Committee, EVEREST trial (Otsuka; a multinational investigation of vasopressin antagonism in heart failure) 2003-7

Chair, Data and Safety Monitoring Board, FUSION-II (Johnson & Johnson; intermittent nesiritide infusion for severe chronic heart failure), 2003-6

Search Committee, Chief Executive Officer, Tufts Medical Center, 2003.

Board of Trustees, Tufts-New England Medical Center, 2003-

Strategic Planning Committee, Board of Trustees, Tufts Medical Center, 2005-

Quality of Care Committee, Board of Trustees, Tufts Medical Center, 2012- Chair,

Heart Failure Society of America Advocacy Committee, 2005-2007

Chair, Data and Safety Monitoring Board, Heart Failure Clinical Research Network, National Heart, Lung, and Blood Institute, 2007

American College of Cardiology, Advocacy Committee, 2005-2007

Data and Safety Monitoring Board, ATHENA Trial (Sanofi; dronedarone inpatients with atrial fibrillation), 2006-9

Medicare Coverage Advisory Council, 2007-2009

International Advisory Committee, Inter-University Cardiovascular Institute of the Netherlands (Netherlands Heart Institute), 2008-

Heart Failure Society of America Advocacy Committee, 2009-

CMS/The Joint Commission/ACC/AHA AMI/Heart Failure Technical Expert Panel, 2009- ACGME Advisory Committee for Advanced Heart Failure and Transplant Cardiology, 2010-

American College of Cardiology, Council on Academic Cardiology, 2010- Chair, 2014- National Heart Lung and Blood Institute, Workshop on Heart Failure Prevention. Co-Chair, 2011.

Heart Failure Society of America, CEO Search Committee, Chair. 2011.

American College of Cardiology, member CardioServe Research Panel, 2011-2013

Patient-Centered Outcomes Research Institute (PCORI) scientific reviewer, 2012-

American College of Cardiology, member, COCATS TF 8 Report on Cardiovascular Training in Heart Failure, 2012-13; 2014-15

Heart Failure Society of America, Nominating Committee Chair, 2014-2015

Board of Trustees, Minuteman Health, 2012-

American College of Cardiology, member (ex-officio) Publications and Editorial Coordination Committee, 2014-

American College of Cardiology, member, Compensation Committee, 2014-

Centers for Medicare and Medicaid Services, MACRA Clinical Advisory Committee, 2016- American Heart Association, Massachusetts Affiliate, Executive Leadership Team, 2016-

American College of Cardiology, member, Health Affairs Committee, 2018-

U.S. Food and Drug Administration, member, Endocrinologic & Metabolic Drug Advisory Committee, 2018-

BIBLIOGRAPHY

I. ARTICLES

1. Beato, M., Kalimi, M., Konstam, M.A., Feigelson, P.: Interaction of glucocorticoids with rat liver nuclei: studies on the nature of the cytosol transfer factor and the nuclear acceptor site. *Biochemistry* 12:3372-3379, 1973.
2. Chasin, L.A., Feldman, A., Konstam, M.A., Urlaub, G.: Reversion of a Chinese hamster cell autotrophic mutant. *Proc. Natl. Acad. Sci. USA* 71:718-722, 1974.

3. Reiffel, J.A., Bigger, J.T., Konstam, M.A.: The relationship between sinoatrial conduction time and sinus cycle length during spontaneous sinus arrhythmia in adults. *Circulation* 50:924-934, 1974.
4. Konstam, M.A., McLoud, T., Stark, P.: Radiological-pathological correlation: tracheobronchial tuberculosis. *Applied Radiology* 7: 125-127, 1978.
5. Konstam, M.A., Novelline, R.A., Athanasoulis, C.A.: Aberrant hepatic artery: a potential cause for error in the angiographic diagnosis of traumatic liver hematoma. *Gastrointest. Radiol.* 4:43-45, 1979.
6. Konstam, M.A., Levine, B., Strauss, H.W., McKusick, K.A.: Left superior vena cava to left atrial communication diagnosed with radionuclide angiocardiology and with differential right to left shunting. *Am. J. Cardiol* 43:149-153, 1979.
7. Konstam, M.A., Strauss, H.W., Alpert, N.M., Miller, S.W., Murphy, R.X., Greene, R.E., McKusick, K.A.: Noninvasive estimation of pulmonary arterial pressure by analysis of pulmonary blood flow distribution. *J. Nucl. Med* 20:923-927, 1979.
8. Santini, D., Fox, D., Kloner, R.A., Konstam, M.A., Rude, R.E., Lorell, B.: Pulmonary hypertension in systemic lupus erythematosus: a case report. *Clin. Cardiol.* 3:406-411, 1980.
9. Konstam, M.A., Wynne, J., Holman, B.L., Brown, E.J., Neill, J.M., Kozlowski, J.: Use of equilibrium (gated) radionuclide ventriculography to quantitate left ventricular output in patients with and without left-sided valvular regurgitation. *Circulation* 64:578-585, 1981.
10. Colucci, W.S., Alexander, R.W., Williams, G., Rude, R.E., Holman, B.L., Konstam, M.A., Wynne, J., Mudge, G.H., Braunwald, E.: Decreased lymphocyte beta adrenergic receptor density in patients with heart failure and tolerance to the beta adrenergic agent pirbuterol. *N. Engl. J. Med.* 305:185-190, 1981.
11. Scott, J.A., Konstam, M.A., Kolodny, G. M.: Absence of a direct chronotropic effect of vasopressin on the myocardial cell. *Pharmacology* 24:57-60, 1982.
12. Konstam, M.A., Tu'meh, S., Wynne, J., Beck, J.R., Kozlowski, J.: Effect of exercise on erythrocyte count and on blood activity concentration following Technetium-99m in-vivo red blood cell labeling. *Circulation* 66:638-42, 1982.
13. Tu'meh, S.S., Holman, B.L., Wynne, J., Konstam, M.A., Kozlowski, J.F., Neumann, A.L.: Scintigraphic diagnosis of tricuspid regurgitation. *Radiology* 145:463-6, 1982.
14. Isner, J.M., Carter, B.L., Bankoff, M.S., Konstam, M.A., Salem, D.N.: Computed tomography in the diagnosis of pericardial heart disease. *Ann. Intern. Med.* 97:473, 1982.
15. Rabinovitch M., Konstam, M.A., Gamble, W.J., Papanicalaou, N., Aronovitz, M.J., Treves, S., Reid, L.: Changes in pulmonary blood flow effect in vascular response to chronic hypoxia in rat. *Circ. Res.* 52(4):432-41, 1983.
16. Konstam, M.A., Idoine, J., Wynne, J., Grossman, W., Cohn, L., Beck, J.R., Kozlowski, J., Holman, B.L.: Right ventricular function in pulmonary hypertensive adults with and without atrial septal defects. *Am. J. Cardiol.* 51:1144-8, 1983.

17. Salem, D.N., Isner, J.M., Hopkins, P., Konstam, M.A.: Ergonovine provocation in post partum myocardial infarction. *Angiology* 35:110-114, 1984.
18. Isner, J.M., Konstam, M.A., Fortin, R.V., Lefebvre, M., Salem, D.N.: Delayed thrombolysis of streptokinase-"resistant" occlusive thrombus: Documentation by pre- and post-mortem coronary angiography. *Am. J. Cardiol.* 52:210-11, 1983.
19. Schmierer, J.A., Isner, J.M., Konstam, M.A., Salem, D.N.: Catheter fragmentation: a potential source of catheter embolus. *Catheterization and Cardiovascular Diagnosis* 9:595-599, 1983.
20. Konstam, M.A.: Evaluating coronary artery disease. *J. Nuc. Med. Tech.* 11:157-162, 1983.
21. Isner, J.M., Clarke, R.H., Pandian, N.G., Donaldson, R.F., Salem, D.N., Konstam, M.A., Payne, D.D., Cleveland, R.J.: Laser myoplasty for hypertrophic cardiomyopathy: initial in-vitro experience in human post mortem hearts and in vivo experience in a canine model (transarterial) and human patient (intra-operative). *Am. J. Cardiol.* 53:1630-6, 1984.
22. Konstam, M.A., Salem, D.N., Isner, J.M., Zile, M.R., Kahn, P.C., Bonin, J.D., Levine, H.J.: Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure-volume relationship. *Am. J. Cardiol.* 54:132-6, 1984.
23. Salem, D.N., Konstam, M.A., Isner, J.M., Bonin, J.D.: Comparison of effects on left ventricular ejection fraction of iopamidol and renografin during left ventriculography and coronary arteriography. *Investigative Radiology* 19:5203-5205, 1984.
24. Konstam, M.A., Kahn, P.C., Curran, B.H., Idoine, J., Wynne, J., Holman, B.L.: Accuracy of equilibrium (gated) radionuclide ejection fraction measurement in the pressure or volume overloaded right ventricle. *Chest* 86:681-687, 1984.
25. Isner, J.M., Michlewitz, H., Donaldson, R.F., Konstam, M.A., Salem, D.N., Clarke, R.H.: Laser-assisted debridement of aortic valve calcium. *Am. Heart J.* 109:442-452, 1985.
26. Salem, D.N., Hymanson, A.S., Isner, J.M., Bankoff, M., Konstam, M.A.: Congenital pericardial defect diagnosed by computed tomography. *Catheterization and Cardiovascular Diagnosis* 11:75-79, 1985.
27. Isner, J.M., Donaldson, R.F., Fumai, J.T., Deckelbaum, K.I., Pandian, N.G., Clarke, R.H., Konstam, M.A., Salem, D.N., Bernstein, J.S.: Factors contributing to perforations resulting from laser coronary angioplasty. *Circulation.* 72:II 191-200, 1985.
28. Konstam, M.A., Cohen, S.R., Salem, D.N., Conlon, T.P., Isner, J.M., Das, D., Zile, M.R., Levine, H.J., Kahn, P.C.: Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure. *J. Am. Coll. Cardiol.* 5:1326-1334, 1985.
29. Deckelbaum, L.I., Isner, J.M., Konstam, M.A., Salem, D.N.: Catheter-induced versus spontaneous spasm: do these coronary bedfellows deserve to be estranged? *Am. J. Med.*, 79:1-4, 1985.

30. Massie, B., Bourassa, M., DiBianco, R., Hess, M., Konstam, M., Likoff, M., Packer, M.: Long term oral amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. *Circulation* 71:963-971, 1985.
31. Salem, D.N., Findlay, S.R., Isner, J.M., Konstam, M.A., Cohen, P.F.: Comparison of histamine releasing effects of ionic and nonionic radiocontrast media. *Am. J. Med.*, 80:382-4, 1986.
32. Simons, M., Isner, J.M., Pandian, N.G., Konstam, M.A., McInerney, K.P., Caldeira, M.E.: Non-invasive evaluation of cardiac amyloidosis. *Echocardiography*, 2:401-408, 1985.
33. Konstam, M.A., Cohen, S.R., Weiland, D.S., Martin, T.T., Das, D., Isner, J.M., Salem, D.N.: Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. *Am. J. Cardiol.*, 57:242-248, 1986.
34. Isner, J.M., Donaldson, R.F., Deckelbaum, K.I., Clarke, R.H., Laliberte, S.M., Ucci, A.A., Salem, D.N., Konstam, M.A.: The excimer laser: gross, light microscopic, and ultrastructural analysis of potential advantages for use in laser therapy of cardiovascular disease. *J. Am. Coll. Cardiol.* 6:1102-9, 1985.
35. Salem, D.N., Konstam, M.A., Isner, J.M., Bonin, J.D.: Comparison of the electrocardiographic and hemodynamic responses to ionic and nonionic radiocontrast media during left ventriculography: a randomized double-blind study. *Am. Heart J.*, III:533-6, 1986.
36. Roberts, D.J., Isner, J.M., Deckelbaum, L.I., Konstam, M.A., Salem, D.N.: Acute myocardial infarction, normal coronary arteries, and catheter-induced spasm. *Am. J. Cardiol.* 58:360-1, 1986.
37. Konstam M.A., Cohen S.R., Salem D.N., Das D., Aronovitz M, Brockway B: Amrinone effect on right ventricular function; predominance of afterload reduction. *Circulation*, 74:35966, 1986.
38. Weiland, D.S., Konstam, M.A., Salem, D.N., Martin, T.T., Cohen, S.R., Zile, M.R., Das, D.: Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure. *Am. J. Cardiol.* 58:1046-1050, 1986.
39. Isner, J.M., Salem, D.N., Desnoyers, M.R., Hougen, T.J., Mackey, W.C., Pandian, N.G., Eichhorn, E.J., Konstam, M.A., Levine, H.J.: Treatment of calcific aortic stenosis by balloon valvuloplasty. *Am. J. Cardiol.* 59:313-317, 1987.
40. Kaplan, J.D., Isner, J.M., Karas, R.H., Halaburka, K.R., Konstam, M.A., Hougen, T.J., Cleveland, R.J., Salem, D.N.: In vitro analysis of mechanisms of balloon valvuloplasty of stenotic mitral valves. *Am. J. Cardiol.* 59:318-323, 1987.
41. Konstam, M.A., Hill, N.S., Bonin, J.P., Isner, J.M.: Prostaglandin mediation of hemodynamic responses to pulmonary microembolism in rabbits: effects of ibuprofen and meclufenamate. *Exp. Lung Res.*, 12:331-345, 1987.
42. Konstam, M.A., Weiland, D.S., Conlon, T.P., Martin T.T., Cohen S.R., Eichhorn, E.J., Isner, J.M., Zile, M.R., Salem, D.N.: Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart

- failure secondary to ischemic or dilated cardiomyopathy. *Am. J. Cardiol.*, 59:1131-1137, 1987.
43. Biddle, T.L., Benotti, J.R., Creager, M., Faxon, D.P., Firth, B.G., Fitzpatrick, P.G., Konstam, M.A., Krebs, C., Walton, L.H., Kershner, R.P., Jacobsen, J., Luczkowec, C.A., Montenegro, M.J., Tandon, P.K., Fitzpatrick, S., Swartz, R.P.: Comparison of intravenous milrinone and dobutamine for congestive heart failure. *Am. J. Cardiol.*, 59:1345-1350, 1987.
 44. Konstam, M.A., Salem, D.N.: Diagnosis of cardiac transplant rejection: time for a new approach. *Newsletter of the Society of Cardiovascular Pathology*, 2:8, 1987.
 45. Konstam, M.A., Weiland, D.S., Salem, D.N.: Mitral regurgitation volume and effect of vasodilators in severe left ventricular failure. *Cardiology Board Review*, 4:63-77, 1987.
 46. Salem, D.N., Berner, S., Eichhorn, E.J., Sherman, L., Konstam, M.A.: Digitalis therapy for congestive heart failure: is the jury still out? *Pharmacotherapy*, 8:319-323, 1988.
 47. Eichhorn, E.J., Konstam, M.A., Weiland, D.S., Roberts, D.J., Martin, T.T., Stransky, N.B., Salem, D.N.: Differential effects of milrinone and dobutamine on right ventricular preload, afterload, and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am. J. Cardiol.*, 60:1329-1333, 1987.
 48. Konstam, M.A., Aronovitz, M.J., Runge, V.M., Kaufman, D.M., Brockway, B.A., Isner, J.M., Katzen, N.A., Dresdale, A.R., Diehl, J.T., Kaplan, E., Payne, D.D., Cleveland, R.J.: Magnetic resonance imaging with gadolinium-DTPA for detecting cardiac transplant rejection in rats. *Circulation* 78:III-87-94, 1988.
 49. Brill, D.M., Konstam, M.A.: Right ventricular function in ischemic and non-ischemic heart disease. *Cardio.*, June, 1988:57-66.
 50. Diehl, J.T., Eichhorn, E.J., Konstam, M.A., Payne, D.D., Dresdale, A.R., Bojar, R.M., Rastegar, H., Stetz, J.J., Salem, D.N., Connolly, R.J., Cleveland, R.J.: Efficacy of retrograde coronary sinus cardioplegia in patients undergoing myocardial revascularization: a prospective randomized trial. *Ann. Thorac. Surg.* 45:5956-602, 1988.
 51. Kaplan, E., Dresdale, A.R., Diehl, J. T., Aronovitz, M.J., Konstam, M.A., Katzen, N., Gould, K., Isner, J., Connolly, R.J., Payne, D.D., Cleveland, R.J.: Donor specific transfusion and cardiac xenografts. *Transplantation* 46:605-7, 1988.
 52. Palabrica TM, Furie BC, Konstam MA et al: Thrombus Imaging in Primate Models using Anti-PADGEM Antibodies Specific for Activated Platelets. *Proceedings of the National Academy of Science*, 86:1036-1040, 1989.
 53. Eichhorn EJ, Diehl JT, Konstam MA, Payne DD, Salem DN, Cleveland RJ: Left ventricular inotropic effect of atrial pacing after coronary artery bypass grafting. *Am J Cardiol*, 1989;63:687-692.
 54. Eichhorn EJ, Konstam MA, Salem DN, Isner JM, Deckelbaum L, Stransky NB, Metherall JA, Toltzis HI: Dipyridamole thallium-201 imaging pre- and post-coronary angioplasty for assessment of regional myocardial ischemia in humans. *Am Heart J.* 117:1203-1209, 1989.

55. Kaplan E, Dresdale AR, Diehl JT, Katzen NA, Aronovitz MJ, Konstam MA, Payne DD, Cleveland RJ: Total lymphoid irradiation and discordant cardiac xenografts. *J Heart Transplantation* 9: 11-13, 1990.
56. Salem DN, Desnoyers MR, Berman AD, Konstam MA: Coronary angioplasty and thrombolysis for acute myocardial infarction: is two a crowd? *Am J Med*, 86: 259-261, 1989.
57. Eichhorn EJ, Diehl JT, Konstam MA, Payne DD, Salem DN, Cleveland RJ: Protective effects of retrograde versus antegrade cardioplegia on right ventricular systolic and diastolic function during coronary bypass surgery. *Circulation*, 79:1271-1281, 1989.
58. Konstam MA, M.D., Brockway BA, Aronovitz MJ, Ramberg K, Palabrica TM, M.D., Otradovec CL, Cooper A, M.D., Hill N, M.D: Kinetics of Pulmonary Platelet Deposition and Clearance During Thrombin-Induced Microembolism in Rabbits. *Exp Lung Res*, 1989;15:867-879.
59. Diehl JT, Kaplan E, Dresdale AR, Kreis A, Konstam MA, Ross IM, Connolly RJ, Pandian NG, Payne DD, Cleveland RJ: Effects of atrial cardioplegia on the ischemic right ventricle after acute coronary artery occlusion and reperfusion. *Ann Thorac Surg*, 1989;48:829-34.
60. Konstam MA, Kronenberg MW, Udelson JE, Metherall J, Dolan N, Edens TR, Howe DM, Yusuf S, Youngblood M, Toltsis H: Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure: relation to right ventricular volumes. *Circulation*, 1990;81(Suppl III):III-115 - III-122.
61. McEnroe CS, O'Donnell TF, Yeager A, Konstam M, Mackey WC: Comparison of ejection fraction and Goldman risk factor analysis to dipyridamole-thallium-201 studies in the evaluation of cardiac morbidity following aortic aneurysm surgery. *J Vasc Surg*, 1990;11:497-504.
62. Pandian NG, Kreis A, Weintraub A, Motarjeme A, Desnoyers M, Isner JM, Konstam M, Salem DN, Millen V: Realtime intravascular ultrasound imaging in humans. *Am J Cardiol*, 1990 65:1392-6.
63. Pandian NG, Weintraub A, Kreis A, Schwartz SL, Konstam MA, Salem DN: Intracardiac, intravascular, two-dimensional high frequency ultrasound imaging of pulmonary artery and its branches in humans and animals. *Circulation*, 1990;81:2007-2012.
64. Smith J, Udelson JE, Salem DN, Konstam MA: Determinants of survival in patients with congestive heart failure. *Cardio*, 1990;7:34-42.
65. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. *Circulation*, 1990;82:774-780.
66. Pandian NG, Schwartz SL, Hsu TL, Weintraub AR, Katz SE, Aronovitz M, Konstam MA, Salem DN, Kreis A: Intracardiac echocardiography: experimental observations on intracavitary imaging of cardiac structures with 20 MHz ultrasound catheters. *Echocardiography* 1991; 8:1271-34.

67. Konstam MA, Aronovitz MJ, Runge VM, Brockway BA, Isner JM, Foster EA, Kaufman DM, Diehl JT, Dresdale AR, Katzen NA, Kaplan E, Payne DD: Magnetic Resonance Imaging in Ischemic Injury Following Cardiac Transplant in Rats. *J Heart Transplantation*, 1991;10:750-756.
68. Pandian NG, Schwartz SL, Weintraub AR, Hsu TL, Konstam MA, Salem DN: Intracardiac echocardiography: current developments. *International J Card Imaging*. 1991; 6:207-219.
69. Schwartz SL, Pandian NG, Kumar R, Katz SE, Kusay BS, Aronovitz M, Konstam MA, Salem DN: Intracardiac echocardiography during simulated aortic and mitral balloon valvuloplasty: in vivo experimental studies. *Am Heart J*, 1992;123:665-673.
70. Kubo SH, Gollub S, Bourge R, Rhako P, Cobb F, Jessup M, Brozena S, Brodsky M, Kirlin P, Shanes J, Konstam M, Gradman A, Morledge J, Cinquegrani M, Singh S, LeJemtel T, Nicklas J, Troha J, Cohn JN: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. *Circulation*, 1992;85:942-949.
71. Konstam MA, Kronenberg MW, Udelson JE, Kinan D, Metherall J, Dolan N, Edens T, Howe D, Kilcoyne L, Benedict C, Youngblood M, Barrett JF, Yusuf S, for the SOLVD Investigators: Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. *Am J Cardiol*, 1992;69:1591-1595.
72. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, the SOLVD Investigators: Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. *Circulation*, 1992;86:431-438.
73. Kimmelstiel CD, Udelson J, Salem DN, Rastegar H, Bojar RM, Konstam MA: Recurrent angina due to a left internal mammary artery to pulmonary artery fistula. *Am Heart J*, 1993;125:234-6
74. Homoud M, Chuttani K, Konstam MA: Positive inotropic agents in congestive heart failure. *Coronary Artery Disease*, 1993;4:44-52.
75. Vannan MA, Taylor DJE, Webb-Peploe MM, Konstam MA: ACE inhibitors after myocardial infarction. *Brit Med J*, 1993;306:531-2.
76. Udelson JE, Surks H, Konstam MA: The importance of left ventricular diastolic dysfunction and right ventricular performance in the heart failure syndrome. *Current Opinion in Cardiology*. 1993; 8:383-396.
77. Konstam MA, Flores EA: The role of the right heart in left heart failure. *Resident and Staff Physician*, 1994;40:45-49.
78. Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict CR, Yusuf S, Konstam MA, for the SOLVD Investigators: Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. *Circulation*, 1993;88:481-491.

79. Rhodes J, Udelson JE, Konstam MA, Marx GR, Hijazi ZM, Bova SA, Fulton DR: A new noninvasive method for the estimation of peak dP/dt . *Circulation*, 1993;88:2693-2699.
80. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators: Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. *Circulation*, 1993;88:2277-2283.
81. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez AR, Griffith JL, Shea NL, Oates E, Konstam MA: Predicting recovery of severe regional ventricular dysfunction: comparison of resting scintigraphy with thallium 201 and technetium 99m-sestamibi. *Circulation*, 1994; 89:2552-61.
82. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during longterm therapy with angiotensin-converting enzyme inhibitor. *Am J Cardiol*, 1994;73:488-493.
83. Schwartz SL, Kusay BS, Pandian NG, Aronovitz M, Konstam MA, Salem DN: Utility of in vivo intracardiac 2-dimensional echocardiography in the assessment of myocardial risk area and myocardial dyssynergy during coronary occlusion and reperfusion. *Echocardiography*, 1994;11:71-78.
84. Pouleur HG, Konstam MA, Udelson JE, Rousseau MF, for the SOLVD Investigators: Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. *J Am Coll Cardiol* 1993;22 [Supplement A]: 43A-48A.
85. Konstam V, Turbett A, Konstam MA: A group intervention for cardiac transplantation recipients and their families. *J Appl Rehab Couns*. 1995;26:33-35.
86. Al-Khadra AS, Konstam MA, Salem DN: Treatment of asymptomatic patients with left ventricular systolic dysfunction. *Comprehensive Therapy*. 1994; 20:257-262.
87. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA: The role of revascularization in the management of patients with moderate or severe left ventricular systolic dysfunction. *JAMA*. 1994;272:1528-34.
88. Baker DW, Konstam MA, Bottorff M, Pitt B: Management of heart failure: pharmacologic treatment. *JAMA*. 1994;272:1361-66.
89. Konstam MA, Dracup K, Bottorff MB et al: Quick reference guide for clinicians: heart failure: management of patients with left ventricular systolic dysfunction. *Congestive Heart Failure*. November 1994: 37-50.
90. Konstam MA, Dracup K, Baker D, Bottorff M, Brooks NH, Dacey RA, Dunbar SB, Jackson A, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC: Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction. *J Cardiac Failure* 1995;1:183-7.

91. Konstam MA, Cody RJ: Short-term use of intravenous milrinone for heart failure. *Am J Cardiol.* 1995;75:822-6.
92. Konstam MA: Role of Angiotensin Converting Enzyme Inhibitors in Preventing Left Ventricular Remodeling Following Myocardial Infarction. *European Heart Journal.* 1995; 16 Suppl K:42-8.
93. Benedict C, Francis GS, Johnstone DE, Kubo SH, Kirlin P, Nicklas J, Liang C, Konstam MA, Greenberg B, Yusuf S: Effects of long term therapy on neurohormones in patients with left ventricular dysfunction. *Am J Cardiol.* 1995;75:1151-7.
94. Kimmelstiel CD, Konstam MA: Heart failure in women. *Cardiology.* 1995; 86: 304-9.
95. Kimmelstiel CD, Perrone R, Kilcoyne L, Souhrada J, Udelson J, Smith J, de Bold A, Griffith J, Konstam MA: The effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics, and neurohormonal activation in patients with congestive heart failure. *Cardiology,* 1996,87:46-53.
96. Chuttani K, Metherall JA, Griffith JL, Pauker SG, Oates E, Coleman P, Salem DN, Konstam MA, Udelson JE: Hepatic uptake of thallium-201 chloride in patients with right coronary artery disease. *Am J Cardiol,* 1995;76:1020-4.
97. Konstam MA: Angiotensin converting enzyme inhibition in asymptomatic left ventricular dysfunction and early heart failure. *European Heart Journal.* 1995;16 Suppl N:59-64.
98. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam MA, Probstfield JL, Yusuf S, for the SOLVD Investigators: Prognostic significance of neurohormonal activation in patients with asymptomatic left ventricular dysfunction. *Circulation.* 1996;94:690-697.
99. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, Mottard I, Woods P, Konstam MA, Yusuf S, for the SOLVD Investigators: Baseline quality of life as predictor of mortality and hospitalization in 5025 patients with congestive heart failure. *Am J Cardiol.* 1996;78:890-895.
100. Snapper HJ, Shea NL, Konstam MA, Oates E, Udelson JE. Combined analysis of resting regional wall thickening and stress perfusion with electrocardiographic-gated technetium 99mlabeled sestamibi single-photon emission computed tomography: prediction of stress defect reversibility. *J Nucl Cardiol* 1997;4:3-10.
101. Konstam MA: Calcium channel blockers in heart failure and results of the PRAISE trial. *Cardiologia* 1996; 41 (Suppl 4): 199-204.
102. Patten RD, Kronenberg MW, Benedict CR, Udelson JE, Stewart D, Kilcoyne L, Dolan N, Yusuf S, Konstam MA. Acute and long term effects of the angiotensin converting inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. *American Heart Journal* 1997;134:37-43.
103. Konstam MA, Smith JJ, Patten R, Udelson JE: Calcium channel blockers in heart failure: help or hindrance? *J Card Failure* 1996;2:S251-S257.

104. Konstam V, Surman O, Hijjazi KH, Fierstein J, Konstam MA, Turbett A, Dec GW, Keck S, Mudge G, Flavel C, McCormack M, Hurley L: Marital adjustment in heart transplantation patients and their spouses: a longitudinal perspective. *Am J of Family Therapy* 1998; 26, 147158.
105. Konstam MA: New trends in the interventional treatment of ischaemic heart disease. *European Heart Journal* 1997; 18 (Suppl B), B16-B20.
106. Gheorghide M, Benatar D, Konstam MA, Stoukides CA, Bonow RO: Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. *Am J Cardiol* 1997;80:14H-27H.
107. Konstam, MA: Effect of the dihydropyridine calcium channel antagonist, amlodipine, on mortality and cardiac morbidity in patients with heart failure and left ventricular systolic dysfunction. Results of the PRAISE trial. *Int J Cardiol*. In press.
108. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Effect of antiplatelet agents on survival in patients with left ventricular systolic dysfunction. *J Am Col Cardiol*, 1998; 31(2):419-25.
109. Taylor K, Patten RD, Smith JJ, Aronovitz MJ, Wight J, Salomon RN, Konstam MA: Divergent effects of antitensin converting enzyme inhibition and angiotensin II receptor antagonism on myocardial cellular proliferation and collagen deposition following myocardial infarction in rats. *J Cardiovasc Pharmacol*, 1998;31:654-660.
110. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. *J Am Col Cardiol*. 1998; 31(4):749-53.
111. Konstam MA, Remme WJ: Treatment guidelines in heart failure. *Prog Cardiovasc Dis*. 1998; 41 (Suppl 1):65-72.
112. Patten RP, Aronovitz MJ, Deras-Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME, Konstam MA: Ventricular remodeling in a mouse model of myocardial infarction. *Am J Physiol*. 1998;274:H1812-H1820.
113. Patten RD, Udelson JE, Konstam MA: Ventricular remodeling and its prevention in the treatment of heart failure. *Current Opinion in Cardiology*, 1998;13:162-7.
114. Gregory D, Udelson JE, Konstam MA: Economic impact of beta blockade in heart failure. *Am J Med*. 2000;109(4A):1S-6S.
115. Goldberg RJ, Konstam MA: Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. *Arch Int Med* 1999;159:15-17.
116. Kronenberg MW, Konstam MA, Edens TR, Howe DM, Dolan N, Udelson JE, Benedict C, Stewart D, Yusuf S: Factors influencing exercise performance in patients with left ventricular dysfunction. *J Cardiac Failure*. 1998;4:159-167.
117. Konstam MA: Management of ischemic heart disease: therapeutic options and future directions. *Cardiovasc Drugs and Ther*. 1998;12:239.

118. Konstam MA: Mining gold standards from ivory towers: Quality of care in academic medical centers. *Am Heart J.* 1999;137:987-8.
119. Pitt B, Konstam MA: Overview of angiotensin II receptor antagonists. *Am J Cardiol* 1998;82:47S-49S.
120. Kimmelstiel C, Udelson J, Smith J, Konstam MA: Current concepts in the treatment of patients with heart failure. *ACC Current Journal Review.* July/Aug 1998:39-43.
121. Smith JJ, Konstam MA: Heart Failure: A Case for Sub-specialized Care Management. *Am Heart J.* 1999;138:14-4.
122. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design and population baseline characteristics of the Losartan Heart Failure Survival Study – ELITE II. *J Card Failure.* 1999;5:146-154.
123. Udelson JE, DeAbate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, Konstam MA and the Amlodipine Exercise Trial Investigators: Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure due to left ventricular systolic dysfunction. *Am Heart J.* 2000;139:503-10.
124. Konstam V, Hurley L, Hijjazi K, Perry K, Konstam MA: Positive affect: A neglected group treatment outcome measure in assessing efficacy of psychosocial group interventions in individuals with heart failure. *Group* 1999; 23:37-46.
125. Adams KF, Baughman KL, Dec WG, Elkayam U, Forker AD, Georghiadis M, Hermann D, Konstam MA, Liu P, Massie BM, Patterson JH, Silver MA, Warner Stevenson L: Heart Failure Society of America Guidelines for the Management of Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction – pharmacologic approaches. *J Card Failure,* 1999;5:357-382.
126. Patten RD and Konstam MA: Ventricular remodeling and the renin-angiotensin-aldosterone system. *Congestive Heart Failure,* 2000;Jul-Aug 6 (4):187-192.
127. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, Lewis W, Gradman A, Self KS, Bittner V, Rand W, Kinan D, Smith JJ, Ford T, Segal R, Udelson JE: Effects of Losartan and Captopril on Left Ventricular Volumes in Elderly Patients with Heart Failure: Results of the ELITE Ventricular Function Substudy. *Am Heart J,* 2000;139:1081-7. 128. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B, on behalf of the ELITE II investigators: Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. *Lancet.* 2000;355:1582-7.
129. Krumholz HM, Baker DW, Ashton, CM, Dunbar SB, Friesinger GC. MD, Havranek EP, Hlatky MA, Konstam, MA, Ordin DL., Pina I, Pitt B, Spertus JA: Evaluating Quality of Care for Patients With Heart Failure Volume. *Circulation* 2000; 101:e122-e140.

130. Konstam MA: Progress in heart failure management? Lessons from the real world. *Circulation*. 2000;102:1076-8.
131. Al-Ahmad A, Sarnak MJ, Salem DN, Konstam MA: Cause and Management of Heart Failure in Patients with Chronic Renal Disease. *Seminars in Nephrology*: 2001;21:3-12
132. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam M A, Udelson JE: Comparative Effects of Carvedilol and Metoprolol on Left Ventricular Ejection Fraction in Heart Failure: Results of a Meta-Analysis. *Am Heart J*. 2001;141:899-907.
133. Patel AR, Kuvin JT, Pandian NG, Smith JJ, Udelson JE, Mendelsohn ME, Konstam MA, Karas RH: Heart Failure Etiology Affects Peripheral Vascular Endothelial Function After Cardiac Transplantation. *J Am Col Cardiol*. 37:195-200, 2001.
134. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. *J Am Coll Cardiol* 2001; 38:955-62.
135. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA: Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients with Advanced Heart Failure. *Circulation*. 2001;104:2417-2423.
136. Konstam MA: Relating Quality of Care to Clinical Outcomes in Heart Failure: In Search of the Missing Link. *J Card Failure*, 2001;7:299-301.
137. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ: Cardiovascular thrombotic events in the controlled clinical trials of rofecoxib. *Circulation*, 2001;104:2280-2288.
138. Patel A, Konstam MA: Recent advances in the treatment of heart failure. *Circulation Journal*, 2002;66(2):117-21.
139. Konstam MA: Val-HeFT and Angiotensin Receptor Blockers in Perspective: A Tale of the Blind Man and the Elephant. *J Card Failure*. 2002; Apr 8(2):56-8.
140. Konstam MA, Mann DL. Contemporary Medical Options for Treating Patients with Heart Failure. *Circulation*. 2002;105:2244-2246.
141. Konstam MA, Weir MR: Current perspective on the cardiovascular effect of coxibs. *Cleveland Clinic Journal of Medicine*. 2002;69 (Supplement I):SI-47.
142. Konstam MA: Aspirin and Heart Failure: Square Evidence Meets a Round Patient. *Congestive Heart Failure*. 2003. July/August: 203-205.
143. Konstam MA: Heart Failure Society of America: A Society with a Mission. *J of Cardiac Failure*, 2002; Oct 8(5):275-8.
144. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL; Swedberg C, for the OVERTURE Study Group: Comparison of omapatrilat and enalapril in patients with

- chronic heart Failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). *Circulation* 2002;106:r21-r27.
145. Konstam MA: Improving clinical outcomes with drug treatment in heart Failure: What have trials taught us? *Am J Cardiol*, 2003;91(6A):9D-14D.
146. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, Konstam MA: Effects of angiotensin II receptor blockade versus angiotensin converting enzyme inhibition on ventricular remodeling following myocardial infarction in the mouse. *Clinical Science*, 2003;104(2):109-18.
147. Felker GM, Adams KF, Konstam MA, O'Connor CM, Gheorghide M: The problem of decompensated heart failure: Nomenclature, classification, and risk stratification. *American Heart Journal*, 2003;154(2 suppl):S18-25.
148. Havranek EP, Krumholz HM, Dudley RA, Adams K, Gregory D, Lampert S, Lindenfeld J, Massie B, Pina I, Restaino S, Rich MW, Konstam MA: Aligning quality and payment for heart failure care: defining the challenges. *J Card Failure*. 2003;Aug 9(4):251-4.
140. Konstam MA. Matters of the heart: Assessing the cardiovascular safety of new drugs. *Am Heart J*2003;146:561-2.
150. Konstam MA. "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. *J Card Failure*. 2003;9:1-3.
151. Konstam MA, Udelson JE, Sharpe N. Prevention and reversal of remodeling: an overview. *J Card Failure*. 2002;8:S506-S511.
152. Patel AR, Kuvin JT, DeNofrio D, Kinan D, Sliney KA, Eranki KP, Pandian NG, Udelson JE, Konstam MA, Karas RH. Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. *Am J Cardiol*. 2003;91:897-9.
153. Konstam MA: Colloid Osmotic Pressure: An under-recognized factor in the clinical syndrome of heart failure. *J Am Coll Cardiol*, 2003;42(4):717-8.
154. Konstam MA, Pina I, Lindenfeld J, Packer M: A Device is not a drug. *J Card Failure*. 2003. 9:155-157.
155. Gregory DD, Sarnak MJ, Konstam MA, Pereira B, Salem DN: Impact of Chronic Kidney Disease and Anemia on Hospitalization Expense in Patients with Left Ventricular Dysfunction. *Am J Cardiol*. 2003;92:1300-1305.
156. Shekelle PG. Rich MW. Morton SC. Atkinson CS. Tu W. Maglione M. Rhodes S. Barrett M. Fonarow GC. Greenberg B. Heidenreich PA. Knabel T. Konstam MA. Steimle A. Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials *J Am Coll Cardiol*. 2003;41:1529-38.
157. Udelson JE, Patten RD, Konstam MA: New concepts in post-infarction ventricular remodeling. *Reviews in Cardiovascular Medicine*. 2003;4:S3-S12.

158. Konstam MA, Udelson JE, Anand Is, Cohn JN: Ventricular Remodeling in Heart Failure: A Credible Surrogate Endpoint. *J Card Failure*. 2003;9:350-353.
159. Deng MC. Young JB. Stevenson LW. Oz MC. Rose EA. Hunt SA. Kirklin JK. Kobashigawa J. Miller L. Saltzberg M. Konstam M. Portner PM. Kormos R. Board of Directors of the International Society for Heart and Lung Transplantation. Destination mechanical circulatory support: proposal for clinical standards. *Journal of Heart & Lung Transplantation*. 2003;22:365-9.
160. Liu P, Konstam MA, Force T. Highlights of the 2003 scientific sessions of the Heart Failure Society of America; Las Vegas, Nevada, September 21 to 24, 2003. *J Am Coll Cardiol*. 2004;43:1103-9.
161. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-Effectiveness of Screening with B Type Natriuretic Peptide to Identify Patients with Reduced Left Ventricular Ejection Fraction. *J Am Coll Cardiol* 2004, 43:1019-26.
162. Alsheikh-Ali AA, Wang PJ, Rand W, Konstam MA, Homoud MK, Link MS, N. A. Mark Estes NAM, Salem DN, Al-Ahmad A: Enalapril Treatment and Hospitalization for Atrial Tachyarrhythmias in Patients With Left Ventricular Dysfunction. *Am Heart J* 2004;147: 10611065.
163. Konstam MA, Denofrio D: Endothelin Expression and the Progression of Heart Failure: Exemplifying the Vagaries of Therapeutic Development. *Circulation*, 2004;109(2):143-5.
164. TenBrook JA Jr, Wolf MP, Hoffman SN, Rosenwasser LJ, Konstam MA, Salem DN, Wong JB. Should β -blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. *Journal of Allergy and Clinical Immunology* 2004;113(5):977-82.
165. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF, on behalf of the EARTH investigators: Long-term Effects of Darusentan on LV Remodeling and Clinical Outcomes – The Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH). *Lancet*. 2004;364:347-354.
166. Kimmelstiel C, Levine D, Perry K, Patel AR, Sadaniantz A, Gorham N, Cunnie P, Duggan L, Cotter L, Shea-Albright P, Poppas A, LaBresh K, Forman D, Brill D, Rand W, Gregory D, Udelson JE, Lorell B, Konstam V, Konstam MA. Randomized, Controlled Evaluation of Short- and Long-Term Benefits of Heart Failure Disease Management within a Diverse Provider Network: The SPAN-CHF Trial. *Circulation*, 2004;110(11):1450-5.
167. Konstam MA, Lindenfeld J, Pina IL, Packer M, Lazar RM, Warner Stevenson L. Heart Failure Society of America. Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America. *Journal of Cardiac Failure*. 2004;10:91-100.
168. Konstam MA, Neaton, JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro

- EP Comparison of Losartan and Captopril on Heart Failure – Related Outcomes and Symptomatology from the Losartan Heart Failure Survival Study (ELITE II). *Am Heart J* 2005;150:123-31.)
169. Blomberg PJ, Feingold AD, Denofrio D, Rand W, Konstam MA, Estes NA 3rd, Link MS. Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. *Am J Cardiol.* 2004;93:379-81.
170. Krishnamani R, Nawgiri RS, Konstam MA, Warner K, Salomon RN, DeNofrio D. Fatty infiltration of the right ventricle (adiopitas cordis) – an unrecognized cause of early graft failure following cardiac transplantation, *J Heart Lung Transpl*, 2005 Aug; 24(8):1143-5.
171. Konstam MA, for the Executive Council of the Heart Failure Society of America: Heart Failure Training: A Call for an Integrative, Patient-Focused Approach to an Emerging Cardiology Subspecialty. *J Am Coll Cardiol*, 2004;44:1361–1362.(Reprinted in *J Card Failure*.2004;10:366-7)
172. Soman P, Pandian N, Fiore J, Homoud M, Konstam MA: Reversal of LV Remodeling by Pericardial Tamponade. *J Card Failure* 2005;11:131-133.
173. Liu P, Konstam MA, Force T: Highlights of the 2004 Scientific Sessions of the Heart Failure Society of America. *J Am Coll Cardiol*, 2005 Feb 15; 45(4): 617-25.
174. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanos A, Konstam MA, Baron JA, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. *N Engl J Med*, 2005 Mar 17; 352(11):1092-102.
175. Bridgman P, Aronovitz M, Kakkar R, Oliverio M, Coffman T, Rand W, Konstam MA, Mendelsohn M, Patten R: Gender Specific Patterns of Left Ventricular and Myocyte Remodeling Following Myocardial Infarction in Mice Deficient in the Angiotensin II Type 1a Receptor. *Am J Physiol: Heart And Circ Physiol*, 2005 Aug; 289(2):H586-92
176. Gheorghide M, Orlandi C, Burnett JC, DeMets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA: Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). *J Card Failure*, 2005 May; 11(4):260-9.
177. Gregory D, DeNofrio D, Konstam MA: The Economic Effect of a Tertiary Hospital Heart Failure Program. *J Am Coll Cardiol*, 2005 Aug 16; 46(4):660-6.
178. Konstam MA: Reliability of Ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. *Am J Cardiol*, 2005 Sep; 96(6):867-71.
179. Hedrich O, Finley J, Konstam MA, Udelson JE: Novel neurohormonal antagonist strategies vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. *Heart Failure Clinics* 2005;1:103-127.

180. Konstam MA, Czerska B, Böhm M, Oren RM, Sadowski J, Khanal S, Abraham WT, Wasler A, Dahm JB, Gavazzi A, Gradinac S, Legrand V, Mohacsi P, Poelzl G, Radovancevic B, Van Bakel AB, Zile MR, Cabuay B, Bartus K, Jansen P: Continuous Aortic Flow Augmentation: A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure. *Circulation*. 2005;112(20):3107-14.
181. Gheorghiadu M, Collins SP, Filippatos G, Klein L, Konstam MA, Massie BM, Piña IL, Roland E, Sopko G, Targum S, Tavazzi L, Zannad F for the International Working Group on Acute Heart Failure Syndrome: Acute Heart Failure Syndrome: Current State and Framework for Future Research. *Circulation* 2005;112:3958-3968.
182. Hunt SA. Abraham WT. Chin MH. Feldman AM. Francis GS. Ganiats TG. Jessup M. Konstam MA. Mancini DM. Michl K. Oates JA. Rahko PS. Silver MA. Stevenson LW. Yancy CW. Antman EM. Smith SC Jr. Adams CD. Anderson JL. Faxon DP. Fuster V. Halperin JL. Hiratzka LF. Jacobs AK. Nishimura R. Ornato JP. Page RL. Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines *Circulation*. 2005;112(12):e154-235.
183. Bonow RO. Bennett S. Casey DE Jr. Ganiats TG. Hlatky MA. Konstam MA. Lambrew CT. Normand SL. Pina IL. Radford MJ. Smith AL. Stevenson LW. Burke G. Eagle KA. Krumholz HM. Linderbaum J. Masoudi FA. Ritchie JL. Rumsfeld JS. Spertus JA. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *Circulation*. 2005;112(12):1853-87.
184. Patten RD. Denofrio D. El-Zaru M. Kakkar R. Saunders J. Celestin F. Warner K. Rastegar H. Khabbaz KR. Udelson JE. Konstam MA. Karas RH. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. *Journal of the American College of Cardiology*. 2005;45(9):1419-24.
185. Quiñones MA, Zile MR, Massie BM, Kass DA, Katz AM, Burkhoff D, Kono AT, Simons M, Apstein CS, Cohn JN, Gaasch WH, Givertz MM, Grossmann W, Konstam MA, Lakatta E, Little W, Maurer MS, Mirsky : Chronic Heart Failure: A Report from the Dartmouth Diastole Discourses. *Congestive Heart Failure*. 2006;12(3):162-5.
186. Neaton JD, Gray G, Zuckerman BD, Konstam MA: Key Issues in Endpoint Selection for Heart Failure Trials: Composite Endpoints. *J Cardiac Failure*. 2005;11:567-75
187. Gheorghiadu M. Gottlieb SS. Udelson JE. Konstam MA. Czerwiec F. Ouyang J. Orlandi C. Tolvaptan Investigators. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. *American Journal of Cardiology*. 2006;97:1064-7. 188. Gregory D, Kimmelstiel C, Perry K, Parikh A, Konstam V, Konstam MA: Hospital cost effectiveness of a heart failure disease management program: the SPAN-CHF Trial. *Am Heart J*, 2006 May; 151(5):1013-8.

189. Saberina A, Mueller B, Konstam MA, Wagner DR. Percutaneous continuous aortic flow augmentation for cardiac recovery in a chronic heart failure patient with peripheral vascular disease. *Congestive Heart Failure*. 2006;12(6):343-6.
190. Heart Failure Society of America (Konstam, MA, committee member): HFSA 2006 comprehensive heart failure practice guideline. *J Card Failure*. 2006;12:e1-e122.
191. Konstam MA: Natriuretic Peptides and Cardiovascular Events: More Than a Stretch. *JAMA*. 2007;297(2):212-4.
192. Neaton JD, Normand S, Gelijns A, Starling RC, Mann DL, Konstam MA: Designs for Mechanical Circulatory Support Device Studies. *Journal of Cardiac Failure*. 2007 13(1):63-74.
193. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. *JAMA*. 2007;297:1319-1331.
194. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure The EVEREST Clinical Status Trials. *JAMA*. 2007;297:1332-1343.
195. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA: Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. *J Am Coll Cardiol* 2007;49:2151-9.
196. Mather PJ, Konstam MA. Percutaneous mechanical devices in the management of decompensated heart failure. *Current Heart Failure Reports*. 4(1):43-7, 2007 Mar.
197. Mather PJ, Konstam MA. Newer mechanical devices in the management of acute heart failure. *Heart Failure Reviews*. 12(2):167-72, 2007 Jun.
198. Greenberg B, Czerska B, Abraham WT, Neaton JD, Delgado RM, Mather P, Robert Bourge R, Parker IC, Konstam MA: Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure: The MOMENTUM Trial. *J Cardiac Fail* 2007;13:715-721.
199. Young JB, Abraham WT, Bourge RC, Konstam MA, Stevenson LW. Heart Failure Society of America. Task force 8: training in heart failure endorsed by the Heart Failure Society of America. *Journal of the American College of Cardiology*. 51(3):383-9, 2008 Jan 22.
200. Finley JJ, Konstam MA, Udelson JE: Vasopressin antagonists for treatment of heart failure and hyponatremia. *Circulation*. 2008;118:410-421.
201. O'Connell JB, McCarthy PM, Sopko G, Filippatos GS, Piña IL, Konstam MA, Young JB, Miller LW, Mehra MR, Roland E, Blair JEA, Farrar DJ, Gheorghiade M: Mechanical

- circulatory support devices for acute heart failure syndromes: considerations for clinical trial design. *Heart Failure Reviews*; June 12, 2008: 1382-4147.
202. Konstam MA: Patterns of Ventricular Remodeling following Myocardial Infarction: Clues Toward Linkage Between Mechanism and Morbidity. *JACC Imaging*. 2008 Sep;1(5):592-4.
 203. Konstam MA, Poole-Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GAJ, Guptha S.: Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. *Europ J Heart Failure*. *Eur J Heart Fail*. 2008 Sep;10(9):899-906. Epub 2008 Sep 2.
 204. Greenberg B, Czerska B, Delgado RM, Bourge R, Zile MR, Silver M, Klapholz M, Haeusslein E, Mehra MR, Mather P, Abraham WT, Neaton JD, Brown BS, Parker IC, Konstam MA: Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure, inadequately responsive to medical therapy: Results of the Multi-center Trial of the Orqis® Medical Cancion® System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). *Circulation*. 2008 Sep 16;118(12):1241-9. Epub 2008 Sep 2.
 205. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi SK, Macarie C, Raev D, Wedge P, Konstam MA, Gheorghide M: Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial. *J Am Coll Cardiol*. 2008 Nov 4;52(19):1540-5.
 206. Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghide M; EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. *J Am Coll Cardiol*. 2008 Nov 11;52(20):1640-8.
 207. Brieke B, Krishnamani R, Rocha MJ, Li W, Patten RD, Konstam MA, Patel A, Udelson JE, DeNofrio D: Influence of Donor Cocaine Use on Outcome after Cardiac Transplantation: An Analysis of the United Network for Organ Sharing Thoracic Registry. *J Heart Lung Transplantation*. 2008 Dec;27(12):1350-2. Epub 2008 Oct 26
 208. Patlolla V, Patten RD, DeNofrio D, Konstam MA, Krishnamani R: The Effect of Ventricular Assist Devices on Post-Transplant Mortality: Analysis of United Network for Organ Sharing Thoracic Registry. *J Am Coll Cardiol*. 2009 Jan 20;53(3):264-71.
 209. Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, Liu PP, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghide M : Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. *J Am Coll Cardiol*. 2009 Jan 20;53(3):254-63.
 210. Konstam MA. Antithrombotic therapy in heart failure: WATCHful wondering. *Circulation*. 2009 Mar 31;119(12):1559-61.

211. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009 Mar 26.
212. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009 Mar 26.
213. Hoekstra JW, O'Neill BJ, Pride YB, Lefebvre C, Diercks DB, Peacock WF, Fermann GJ, Gibson CM, Pinto D, Giglio J, Chandra A, Cairns CB, Konstam MA, Massaro J, Krucoff M: Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. *Ann Emerg Med*. 2009;54(6):779-788.
214. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghide M; Effects of tolvaptan on dyspnoea relief from the EVEREST trials. *Eur Heart J*. 2009;30(18):2233-40.
215. Gregory D, Ordway LJ, McGillivray M, Konstam MA, Denofrio D. A cost-saving strategy for inpatient management of advanced decompensated heart failure patients: the Cardiomyopathy Unit. *J Card Fail*. 2009;15:428-34.
216. Gheorghide M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N; Acute Heart Failure Syndromes International Working Group. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. *Am Heart J*. 2009;157:957-70.
217. Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghide M; EVEREST Investigators: Weight changes after hospitalization for worsening heart failure and subsequent rehospitalization and mortality in the EVEREST trial. *Eur Heart J*. 2009;30:1666-73..
218. Konstam MA, Jessup M, Francis GS, Mann DL, Greenberg B. Advanced heart failure and transplant cardiology: a subspecialty is born. *J Am Coll Cardiol*. 2009 Mar 10;53(10):834-6 and *J Card Fail*. 2009 Mar;15(2):98-100.
219. Konstam MA, Greenberg B: Transforming Health Care Through the Medical Home: The Example of Heart Failure. *J Card Failure*; 2009;15:736-738.

220. Konstam MA, Neaton JD, Dickstein K, et al, for the HEAAL Investigators. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet* 2009; 374: 1840–48.
221. Krishnamani R, DeNofrio D, Konstam MA. Emerging ventricular assist devices for longterm cardiac support *Nat. Rev. Cardiol.* 2010;7:71–76.
222. Weintraub A, Gregory D, Patel AR, Levine D, Venesy D, Perry K, Delano C, Konstam MA: A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: The SPAN-CHF II trial. *J Cardiac Fail* 2010;16:285-292.
223. Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA: Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. *Circ Heart Fail.* 2010; 3:347-53.
224. Zile MR, Colombo PC, Mehra M, Greenberg B, Brown S, Konstam MA. Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). *J Heart Lung Transplant.* 2010 Jan;29(1):86-92.
225. Dunlay SM, Gheorghiade M, Reid KJ, Allen LA, Chan PS, Hauptman PJ, Zannad F, Maggioni AP, Swedberg K, Konstam MA, Spertus JA Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. *Eur J Heart Fail.* 2010 Apr;12(4):367-74.
226. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M; International AHFS Working Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. *Circ Heart Fail.* 2010 Mar;3(2):314-25.
227. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J.* 2010 May;159(5):841-849.e1.
228. Wang NC, Piccini JP, Konstam MA, Maggioni AP, Traver B, Swedberg K, Udelson JE, Zannad F, Cook T, O'Connor CM, Miller AB, Grinfeld L, Gheorghiade M; EVEREST Investigators. Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. *Am J Ther.* 2010 Jul-Aug;17(4):e78-87

229. Konstam MA, Konstam V. Heart failure disease management a sustainable energy source for the health care engine. *J Am Coll Cardiol*. 2010 Jul 27;56(5):379-81.
230. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. *J Am Coll Cardiol*. 2010 Jul 27;56(5):392-406.
231. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkenstein JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. *Circulation*. 2010 Sep 14;122(11):1130-3
232. Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of cardiovascular risk after rofecoxib discontinuation. *Arch Intern Med*. 2010 Dec 13;170(22):2035-6.
233. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. *JACC Cardiovasc Imaging*. 2011 Jan;4(1):98-108.
234. Konstam MA, Udelson JE. Hyponatraemia and vasopressin in heart failure: markers or mediators? *Eur J Heart Fail*. 2011 Mar;13(3):242-4.
235. Konstam V, Gregory D, Chen J, Weintraub A, Patel A, Levine D, Venesy D, Perry K, Delano C, Konstam MA. Health-related quality of life in a multicenter randomized controlled comparison of telephonic disease management and automated home monitoring in patients recently hospitalized with heart failure: SPAN-CHF II trial. *J Card Fail*. 2011 Feb;17(2):151-7.
236. Udelson JE, Konstam MA. Ventricular remodeling fundamental to the progression (and regression) of heart failure. *J Am Coll Cardiol*. 2011 Mar 29;57(13):1477-9.
237. Pang PS, Gheorghiade M, DiHu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. *Am Heart J*. 2011 Jun;161(6):1067-72.
238. Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F, Konstam MA, Spertus JA. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. *Circ Cardiovasc Qual Outcomes*. 2011 Jul;4(4):389-98.
239. Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. *Circ Heart Fail*. 2011 Sep;4(5):578-88.
240. Estes NA 3rd, Sacco RL, Al-Khatib SM, Ellinor PT, Bezanson J, Alonso A, Antzelevitch C, Brockman RG, Chen PS, Chugh SS, Curtis AB, DiMarco JP, Ellenbogen KA, Epstein AE, Ezekowitz MD, Fayad P, Gage BF, Go AS, Hlatky MA, Hylek EM, Jerosch-Herold M, Konstam MA, Lee R, Packer DL, Po SS, Prystowsky EN, Redline S, Rosenberg Y, Van Wagoner DR,

- Wood KA, Yue L, Benjamin EJ. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. *Circulation*. 2011 Jul 19;124(3):36372.
241. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. *Eur Heart J*. 2011 Oct;32(20):2563-72.
242. Konstam MA, Pang PS, Gheorghiade M. Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST. *Eur Heart J*. 2011 Aug 6
243. Patlolla V, Mogulla V, DeNofrio D, Konstam MA, Krishnamani R. Outcomes in patients with symptomatic cerebrovascular disease undergoing heart transplantation. *J Am Coll Cardiol*. 2011 Aug 30;58(10):1036-41.
244. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. *Heart Fail Rev*. 2011 Sep 20.
245. Konstam MA. Despair over disparities: challenges and pathways to "affordable care". *J Am Coll Cardiol*. 2011 Sep 27;58(14):1472-3.
246. Filippatos GS, Desai RV, Ahmed MI, Fonarow GC, Love TE, Aban IB, Iskandrian AE, Konstam MA, Ahmed A. Hypoalbuminaemia and incident heart failure in older adults. *Eur J Heart Fail*. 2011 Oct;13(10):1078-86
247. Konstam MA. Renal function and heart failure treatment: when is a loss really a gain? *Circ Heart Fail*. 2011 Nov 1;4(6):677-9.
248. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, Zimmer C, Orlandi C, Konstam MA. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. *J Card Fail*. 2011 Dec;17(12):973-81
249. Kapur NK, Paruchuri V, Korabathina R, Al-Mohammdi R, Mudd JO, Prutkin J, Esposito M, Shah A, Kiernan MS, Sech C, Pham DT, Konstam MA, Denofrio D. Effects of a percutaneous mechanical circulatory support device for medically refractory right ventricular failure. *J Heart Lung Transplant*. 2011 Dec;30(12):1360-7.
250. Konstam MA. Home monitoring should be the central element in an effective program of heart failure disease management. *Circulation* 2012, 125:820-827.
251. Greenberg BH, Anand IS, Burnett JC Jr, Chin J, Dracup KA, Feldman AM, Force T, Francis GS, Houser SR, Hunt SA, Konstam MA, Lindenfeld J, Mann DL, Mehra MR, Paul SC, Piano MR, Ross HJ, Sabbah HN, Starling RC, Udelson JE, Yancy CW, Zile MR, Massie BM. The Heart Failure Society of America in 2020: a vision for the future. *J Card Fail*. 2012 Feb;18(2):90-3.
252. Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni

- AP. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. *Am Heart J.* 2012 Dec;164(6):884-892.
253. Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. *Eur J Heart Fail.* 2012 Dec;14(12):1401-9.
254. Kiernan MS, Konstam MA. Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure. *J Am Coll Cardiol.* 2012 Nov 13;60(20):2090-1.
255. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M; on behalf of the EVEREST investigators Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *Eur J Heart Fail.* 2012 Oct 11.
256. Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; on behalf of the EVEREST trial investigators. Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial. *Circ Heart Fail.* 2012 Nov 1;5(6):750-758.
257. Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA. Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan [EVEREST] Trial). *Am J Cardiol.* 2012 Dec 15;110(12):1803-8.
258. Greene SJ, Harinstein ME, Vaduganathan M, Subacius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *Am J Cardiol.* 2012 Dec 1;110(11):1657-62.
259. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. *J Card Fail.* 2012 Jul;18(7):515-23.
260. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. *J Cardiovasc Med.* 2012 Jul;13(7):415-22.
261. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M; EVEREST trial investigators Clinical course and predictive value of liver function tests in patients hospitalized for worsening

- heart failure with reduced ejection fraction: an analysis of the EVEREST trial. *Eur J Heart Fail.* 2012 Mar;14(3):302-11.
262. Kociol RD, Konstam MA Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. *Am J Kidney Dis.* 2012 Jul;60(1):8-11.
263. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M: Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *Eur J Heart Fail.* 2013 15:194-202.
264. Konstam MA. RELAX-AHF: rising from the doldrums in acute heart failure. *Lancet.* 2013;381:5-6.
265. Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. *Eur J Heart Fail.* 2013;15:61-8.
266. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction. *Am J Cardiol.* 2013;111:574-81.
267. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail.* 2013;6:47-52.
268. Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M; EVEREST Investigators. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. *J Am Coll Cardiol.* 2013;61:571-9.
269. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M; EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. *Eur Heart J.* 2013;34:835-43.
270. Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subacius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. *Am Heart J.* 2013;165:216-25.
271. Gheorghiade M, Greene SJ, Ponikowski P, Maggioni AP, Korewicki J, Macarie C, Metra M, Grzybowski J, Bubenek-Turconi SI, Radziszewski W, Olson A, Bueno OF, Ghosh A, Deckelbaum LI, Li LY, Patel AR, Koester A, Konstam MA. Haemodynamic effects, safety, and

pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. *Eur J Heart Fail.* 2013;15:679-89.

272. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail.* 2013;6:606-19.

273. Hauptman PJ, Burnett J, Gheorghide M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE; Everest Investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. *J Card Fail.* 2013;19:390-7.

274. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghide M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zaleski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail.* 2013;15:1082-94.

275. Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghide M, Zannad F; EVEREST investigators. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. *Eur J Heart Fail.* 2013;15:1228-35.

276. Greene SJ, Gheorghide M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G; EVEREST Trial investigators. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Eur J Heart Fail.* 2013;15:1401-11.

277. Harold JG, O'Gara PT, Hill JA, Konstam MA. President's page: an urgent call to action: graduate medical education funding and the future of health care. *J Am Coll Cardiol.* 2013;62:1394-5.

278. Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, Nodari S, Butler J, Gheorghide M; EVEREST Trial Investigators. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). *Am J Cardiol.* 2013;112:1763-9.

279. Harold JG, O'Gara P, Hill JA, Konstam MA. President's page: The perfect storm part 2: a rally cry for medical research funding. *J Am Coll Cardiol.* 2013;62:1811-2.

280. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez

EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. *JAMA*. 2013;310:2533-43.

281. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group: Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). *JACC Heart Fail*. 2013 Aug;1(4):308-14.
282. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Marti CN, Yancy CW, Gheorghiade M, Fonarow GC, Konstam MA, Butler J. Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. *JACC Heart Fail*. 2013 Jun;1(3):183-91.
283. Konstam MA. Heart failure in the lifetime of *Musca domestica* (the common housefly). *JACC Heart Fail*. 2013 Apr;1(2):178-80.
284. Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. *JACC Heart Fail*. 2013 Dec;1(6):488-96.
285. Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggioni AP, Swedberg K, Zannad F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M; EVEREST trial investigators. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). *Am J Cardiol*. 2014 Dec 1;114(11):1713-21
286. Morris AA, Butler J, Konstam MA. Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. *J Card Fail*. 2014 Oct;20(10):779-81.
287. Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). *Am J Cardiol*. 2014 Sep 1;114(5):743-50.
288. Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study. *Int J Cardiol*. 2014 May 15;173(3):380-7.
289. Jumean MF, Konstam MA. Heart Failure With Preserved Ejection Fraction: What Is in a Name? *Cardiol Rev*. 2015 Jul-Aug;23(4):161-7. doi: 10.1097/CRD.000000000000057. PMID: 25688660
290. Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K,

- Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M; EVEREST Trial Investigators. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). *Am J Cardiol*. 2015 Mar 15;115(6):790-6. doi: 10.1016/j.amjcard.2014.12.045. PMID: 25728846
291. Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. *JACC Heart Fail*. 2015 Mar;3(3):214-23. doi: 10.1016/j.jchf.2014.11.004. PMID: 25742759
292. Jessup M, Ardehali R, Konstam MA, Manno BV, Mathier MA, McPherson JA, Sweitzer NK. COCATS 4 Task Force 12: Training in Heart Failure. *J Am Coll Cardiol*. 2015 May 5;65(17):1866-76. doi: 10.1016/j.jacc.2015.03.031. PMID: 25777644
293. Rossignol P, Girerd N, Gregory D, Massaro J, Konstam MA, Zannad F. Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. *Int J Cardiol*. 2015 May 6;187:183-9. doi: 10.1016/j.ijcard.2015.03.169. PMID: 25828348
294. Khan H, Greene SJ, Fonarow GC, Kalogeropoulos AP, Ambrosy AP, Maggioni AP, Zannad F, Konstam MA, Swedberg K, Yancy CW, Gheorghiade M, Butler J; EVEREST Trial Investigators. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. *Eur J Heart Fail*. 2015 May 9. doi: 10.1002/ejhf.282. PMID: 25960401
295. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. *Circulation*. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536. PMID: 25986447
296. Klein L, Greenberg BH, Konstam MA, Gregory D, Kociol RD, Johnson MR, de Marco T. Activities and Compensation of Advanced Heart Failure Specialists: Results of the Heart Failure Society of America (HFSA) Survey. *J Card Fail*. 2015 Nov;21(11):924-9. doi: 10.1016/j.cardfail.2015.08.340. Epub 2015 Sep 8. PMID: 26362520
297. Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, Fiuzat M, Gregory D, Wedge P, O'Connor CM, Udelson JE, Konstam MA. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. *Circ Heart Fail*. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259. PMID: 26374918
298. Konstam MA. Hyperkalaemia in heart failure: binding the patient to improved treatment? *Eur J Heart Fail*. 2015 Oct;17(10):997-9. doi: 10.1002/ejhf.404. Epub 2015 Oct 7. PMID: 26443125
299. Konstam MA. Viability, Remodeling, and CABG: Another STICH in the Shroud of Observation-Based Paradigm? *JACC Cardiovasc Imaging*. 2015 Oct;8(10):1130-2. doi: 10.1016/j.jcmg.2015.03.012. PMID: 26481838

300. Konstam MA, Upshaw J. Sisyphus and 30-Day Heart Failure Readmissions: Futility in Predicting a Flawed Outcome Metric. *JACC Heart Fail.* 2016 Jan;4(1):21-3. doi: 10.1016/j.jchf.2015.10.002. Epub 2015 Dec 2. PMID: 26656141
301. Cook TD, Greene SJ, Kalogeropoulos AP, Fonarow GC, Zea R, Swedberg K, Zannad F, Maggioni AP, Konstam MA, Gheorghiade M, Butler J. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). *Am J Cardiol.* 2016 Feb 15;117(4):611-6. doi: 10.1016/j.amjcard.2015.11.050. Epub 2015 Dec 8. PMID: 26742474
302. Vaduganathan M, Marti CN, Mentz RJ, Greene SJ, Ambrosy AP, Subacius HP, Fonarow GC, Chioncel O, Bazari H, Maggioni AP, Zannad F, Konstam MA, Sato N, Gheorghiade M, Butler J; EVEREST trial investigators. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. *Am J Cardiol.* 2016 Apr 1;117(7):1144-50. doi: 10.1016/j.amjcard.2015.12.059. Epub 2016 Jan 14. PMID: 26851146
303. Mecklai A, Subačius H, Konstam MA, Gheorghiade M, Butler J, Ambrosy AP, Katz SD. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. *JACC Heart Fail.* 2016 Jul;4(7):580-8. doi: 10.1016/j.jchf.2016.02.008. Epub 2016 Mar 30. PMID: 27039131
304. Ambrosy AP, Khan H, Udelson JE, Mentz RJ, Chioncel O, Greene SJ, Vaduganathan M, Subacuis HP, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, Butler J. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. *Circ Heart Fail.* 2016 May;9(5). pii: e002458. doi: 10.1161/CIRCHEARTFAILURE.115.002458. PMID: 27140204
305. Auseon AJ, O'Gara PT, Klodas E, Holmes DR Jr, Jackson MJ, Green JS, Konstam MA, Nishimura RA. The Essential Role of Educator Development: 10 Years of the ACC Emerging Faculty Program. *J Am Coll Cardiol.* 2016 May 10;67(18):2177-82. doi: 10.1016/j.jacc.2016.02.052. PMID: 27151350
306. Ferreira JP, Girerd N, Alshalash S, Konstam MA, Zannad F. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. *Eur Heart J.* 2016 Aug;37(31):2455-64. doi: 10.1093/eurheartj/ehw213. Epub 2016 Jun 1. PMID: 27252452
307. Upshaw JN, Konstam MA, Klaveren Dv, Noubary F, Huggins GS, Kent DM. Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation. *Circ Heart Fail.* 2016 Aug;9(8). pii: e003146. doi: 10.1161/CIRCHEARTFAILURE.116.003146. PMID: 27514751
308. Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WH, Felker GM, Shah MR, Braunwald E. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. *JACC Heart Fail.* 2016 Sep;4(9):726-35. doi: 10.1016/j.jchf.2016.06.003. Epub 2016 Aug 10. PMID: 27522631

309. Ibrahim NE, Gaggin HK, Konstam MA, Januzzi JL Jr. Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. *Circ Heart Fail.* 2016 Sep;9(9). pii: e002528. doi: 10.1161/CIRCHEARTFAILURE.115.002528. PMID: 27582282
310. Konstam MA Angiotensin Receptor-Nepriylsin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? *JACC Heart Fail.* 2016 Oct;4(10):823-5. doi: 10.1016/j.jchf.2016.07.013. Epub 2016 Sep 7. PMID: 27614938
311. Butler J, Konstam MA: Dilemmas With Race and Heart Failure Treatment. *Circ Heart Fail.* 2016 Oct;9(10). pii: e003384. No abstract available. PMID: 27707751
312. Konstam MA: Whose Metric Is It, Anyway?: Time for Patients to Assert Quality Control. *JACC Heart Fail.* 2016 Dec;4(12):947-949. doi: 10.1016/j.jchf.2016.10.004. PMID: 27908394
313. Konstam MA: Affordable Care: More Than Just an Act. *JACC Heart Fail.* 2017 Feb;5(2):148-151. doi: 10.1016/j.jchf.2016.12.005. Epub 2017 Jan 18. PMID: 28109782 314. Konstam MA, Abboud FM: Ejection Fraction: Misunderstood and Overrated (Changing the Paradigm in Categorizing Heart Failure). *Circulation.* 2017 Feb 21;135(8):717-719. doi: 10.1161/CIRCULATIONAHA.116.025795. PMID: 28223323
315. Konstam MA, Hill JA, Kovacs RJ, Harrington RA, Arrighi JA, Khera A: The Academic Medical System: Reinvention to Survive the Revolution in Health Care. Academic Cardiology Section Leadership Council of the American College of Cardiology. *J Am Coll Cardiol.* 2017 Mar 14;69(10):1305-1312. doi: 10.1016/j.jacc.2016.12.024. PMID:28279297
316. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE; SECRET of CHF Investigators, Coordinators, and Committee Members: Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. *J Am Coll Cardiol.* 2017 Mar 21;69(11):1409-1419. doi: 10.1016/j.jacc.2016.12.035.
317. Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, Vora AN, Meisel A, Bain RP, Konstam MA, Pencina MJ, Gordon DJ, Mahaffey KW, Hennekens CH, Neaton JD, Pearson GD, Andersson TL, Pfeffer MA, Ellenberg SS: Data monitoring committees: Promoting best practices to address emerging challenges. *Clin Trials.* 2017 Apr;14(2):115-123. doi: 10.1177/1740774516688915. Epub 2017 Feb 1. PMID: 28359194
318. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E; National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

JAMA Cardiol. 2017 Sep 1;2(9):950-958. doi: 10.1001/jamacardio.2017.2198. PMID: 28700781

319. Fonarow GC, Konstam MA, Yancy CW. The Hospital Readmission Reduction Program Is Associated With Fewer Readmissions, More Deaths: Time to Reconsider. *J Am Coll Cardiol*. 2017 Oct 10;70(15):1931-1934. doi: 10.1016/j.jacc.2017.08.046. No abstract available. PMID: 28982507
320. Wessler BS, Ruthazer R, Udelson JE, Gheorghiade M, Zannad F, Maggioni A, Konstam MA, Kent DM. Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. *J Am Heart Assoc*. 2017 Nov 18;6(11). pii: e006121. doi: 10.1161/JAHA.117.006121. PMID: 29151026
321. Upshaw JN, van Klaveren D, Konstam MA, Kent DM. Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. *Am J Med*. 2018 Jun;131(6):676-683.e2. doi: 10.1016/j.amjmed.2017.12.010. Epub 2017 Dec 25. PMID: 29284111
322. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, Kociol RD, Lewis EF, Mehra MR, Pagani FD, Raval AN, Ward C; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*. 2018 May 15;137(20):e578-e622. doi: 10.1161/CIR.0000000000000560. Epub 2018 Apr 12. PMID: 29650544
323. Konstam MA. Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve. *JACC Heart Fail*. 2018 May;6(5):398-400. doi: 10.1016/j.jchf.2018.02.005. Epub 2018 Apr 11. PMID: 29655823
324. Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, Greene SJ, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghiade M, Zannad F. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *Am J Cardiol*. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11. PMID: 29731121
325. Tandan S, Meltzer SN, Davila CD, Konstam MA, LeWinter MM. Eosinophilic Myocarditis With Rapid Progression to Cardiogenic Shock, Managed With Mechanical Support and High-Dose Corticosteroids. *Circ Heart Fail*. 2018 Jun;11(6):e004910. doi: 10.1161/CIRCHEARTFAILURE.118.004910. PMID: 29848515
326. Konstam MA. Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. *Eur J Heart Fail*. 2018 Aug;20(8):1240-1242. doi: 10.1002/ejhf.1205. Epub 2018 May 31. PMID: 29851266

327. Konstam MA. Thirty-day readmissions: Notes from the primordial era of health care metrics. *Am Heart J.* 2018 Jun;200:125-126. doi: 10.1016/j.ahj.2018.01.002. Epub 2018 Jan 8. PMID: 29898840
328. Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. *JACC Heart Fail.* 2018 Aug;6(8):619-632. doi: 10.1016/j.jchf.2018.06.008. PMID: 30071950
329. Konstam MA. The future of cardiovascular care: from affordable care to the academic medical center. *Trans Am Clin Climatol Assoc.* 2018;129:301-311. PMID: 30166724

II. BOOKS, MONOGRAPHS, AND CHAPTERS

1. Konstam, MA, Wynne, J: Radionuclide ventriculography, In: Cohn, PR and Wynne, J, Diagnostic Methods in Clinical Cardiology, Little, Brown and Company, 1982.
2. Konstam, MA and Isner, JM (eds.): The Right Ventricle, Boston, Kluwer Academic Publishers; 1988.
3. Konstam, MA and Pandian, N: Assessment of right ventricular function. In: Konstam, M.A. and Isner, J.M.: The Right Ventricle, Boston, Kluwer Academic Publishers; 1988.
4. Konstam, MA and Levine, HJ: Effects of afterload and preload on right ventricle systolic performance. In: Konstam, M.A. and Isner, JM: The Right Ventricle, Boston, Kluwer Academic Publishers; 1988.
5. Eichhorn, EJ, Konstam, MA: Quantitation of aortic regurgitation. In: Gaasch W. and Levine H.J., Aortic Regurgitation, Martinus-Nijhoff; 1988.
6. Konstam, MA and Weintraub, AR: Congestive heart failure. In: Harrington, J.T.: Consultation in Internal Medicine. Philadelphia, B.C. Decker, 1990.

7. Konstam, MA and Udelson, JE: Right Heart Failure. In Hosenpud JD, Greenberg B.: Congestive Heart Failure: Pathophysiology, Differential Diagnosis and Comprehensive Approach to Therapy. New York, Springer-Verlag;1993.
8. Smith JJ, Udelson JE, Konstam MA, Salem DN: Use of the implantable cardioverter defibrillator in patients awaiting heart transplant. In Estes NAM, Manolis AS, Wang PJ: Implantable Cardioverter-Defibrillators. New York, Marcel Dekker; 1994.
9. Konstam MA, Dracup K, Baker D, Bottorff M, Brooks NH, Dacey RA, Dunbar SB, Jackson A, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC: Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction. Agency for Health Care Policy and Research, U.S. Dept. of Health and Human Services, Rockville, MD; 1994.
10. Konstam MA, Kimmelstiel C: Milrinone. In Messerli FH: Cardiovascular Drug Therapy, 2nd Edition. W.B.Saunders Company, Philadelphia, 1996.
11. Konstam, MA and Udelson, JE: Assessment of right ventricular function. In: Peterson, KL and Nicod, P: Cardiac Catheterization: Methods, Diagnosis, and Therapy. W.B. Saunders; 1997.
12. Konstam MA, Patten RD, Kimmelstiel CD, Halin NJ, Namyslowski JB, Greenfield AJ: Cardiac Angiography. In Uretsky BF: Diagnostic Catheterization. Blackwell Scientific Publications, Malden, MA. 1997.
13. Konstam MA, Kimmelstiel CD: Economics of Heart Failure. In: Balady GJ, Pina IL (eds). *Exercise and Heart Failure*. Armonk, N.Y.:Futura Publishing Co; 1997.
14. Kimmelstiel C, Konstam MA: Management of Heart Failure. In: Harrington JT (ed): Consultation in Internal Medicine (2nd Edition of above). B.C. Decker Inc. Philadelphia, 1997.
15. Konstam MA, Pearson TA, Roberts WC, Smith SC (guest editors): A Symposium: Current focus in treating and managing coronary artery disease and heart failure. *Am J Cardiol*, Oct 30, 1997.
16. Patten R, and Konstam MA: Post myocardial infarction left ventricular dysfunction and heart failure. In: Sharpe N (ed): *Heart Failure Management 2000*. London, Martin Dunitz Ltd. 1999.
21. 30th Bethesda Conference: The Future of Academic Cardiology. *J Am Coll Cardiol*. 1999;33:1096-1135.
22. Patel A, Konstam MA: Assessment of the Patient with Heart Failure. In Crawford MH and DiMarco JP (eds.): *Cardiology*. London, Mosby, 2001.
23. Konstam MA, Baker DW: Clinical Practice Guidelines in Heart Failure: State of the Art in the United States. In Kitabatake A, Sasayama S, Francis GS (eds): *Heart Failure: New Frontiers in Cardiology*, Springer-Verlag, Tokyo, 2000.
24. Konstam MA and Udelson JE: Right Heart Failure. In: Hosenpud JD and Greenberg BH (eds): *Congestive Heart Failure (Second Edition)*. Lippincott, New York, 1999.

25. Kimmelstiel CD, Konstam MA. Congestive Heart Failure. In: Wachter RM, Goldman L, Hollander H (eds): Hospital Medicine, Williams and Wilkins, Baltimore, MD, 2000.
26. Mechanical Cardiac Support Writing Group: Mechanical Cardiac Support 2000: Current Applications and Future Trial Design. J Am Coll Cardiol. 2001;Vol 37, No.1.
27. Konstam MA and Patten RD: Antagonism of the Renin-Angiotensin System in Heart Failure. In Mann D (ed): Heart Failure: A Companion to Braunwald's Heart Disease, Elsevier, London, 2002.
28. Morin DP, Konstam MA, Mendelsohn ME, Udelson JE: Heart failure in women: epidemiology, gender differences in pathophysiology, and implications for therapy. In Shaw LJ, Hachamovitch R, Redberg R (eds): Women and Coronary Disease – Our Evolving Understanding of Diagnosis and Treatment; 2003.
29. Patel A, Konstam MA: Assessment of the Patient with Heart Failure. In Crawford MH and DiMarco JP, Paulus WJ (eds.): Cardiology. Second and Third Editions. London, Mosby, 2003; 2010.
30. Patten RD and Konstam MA: Inhibition of the Renin-Angiotensin-Aldosterone System. In Greenberg B (ed): Myocardial Remodeling: Mechanisms and Treatment. Marcel Dekker, 2003.
31. Kimmelstiel C, DeNofrio D, Konstam MA: Heart Failure. In: Wachter RM, Goldman L, Hollander H (eds): Hospital Medicine, Williams and Wilkins, Baltimore, MD, 2004.
32. Felker GM, Adams KF, Konstam MA, O'Connor CM, and Gheorghiade M: The Problem of Decompensated Heart Failure: Nomenclature, Classification, and Risk Stratification. In: O'Connor C, Gattis-Stough W, Adams K, Gheorghiade Mihai (eds): Managing Acute Decompensated Heart Failure: A Clinician's Guide for Diagnosis and Treatment. Martin Dunitz, London.
33. Finley J, Hedrich O, Konstam MA, Udelson JE: Arginine vasopressin antagonism in heart failure. In: Yancy CW, Young JB (eds.): Therapeutic Strategies in Heart Failure. Clinical Publishing, Oxford, 2008.
34. Katz AM, Konstam MA: Heart Failure. Lippincott Williams & Wilkins, 2008.
35. Konstam MA, Udelson JE: Vasopressin antagonists in the management of heart failure. In: Braunwald E (ed.): Heart Disease (electronic). Saunders, 2011.
36. Kiernan MS, Udelson JE, Sarnak M, Konstam MA: Cardiorenal syndrome: Definition; prognosis; and pathophysiology. UpToDate, 2011.
<http://www.uptodate.com/patients/content/topic.do?topicKey=~mSmy4hGbdAy>
37. Konstam MA: Medical therapy for chronic heart failure. In: O'Gara PT (ed.): Adult Clinical Cardiology Self-Assessment Program (ACCSAP) version 8. American College of Cardiology, 2012.

